On April 29, GPCR scientists walked into Pressed Cafe in Boston's Prudential Center and did something The general manager helped us set up personally, and the space felt warm and welcoming from the moment

Significantly, we show that GRKs generate distinct phosphorylation barcodes in intracellular loop 2 ( regulate recruitment of the scaffolding protein β-arrestin 2 (βarr2) to APH1A and γ-secretase-mediated Aβ generation the molecular and structural determinants of the APH1A-βarr2 interaction that critically regulate Aβ generation

September 2022 "Chemerin is the product of the RARRES2 gene which is secreted as a precursor of 143 amino acids. That precursor is inactive, but proteases from the coagulation and fibrinolytic cascades, as well as from inflammatory reactions, process the C-terminus of chemerin to first activate it and then subsequently inactivate it. Chemerin can signal via two G protein-coupled receptors, chem1 and chem2, as well as be bound to a third non-signaling receptor, CCRL2. Chemerin is produced by the liver and secreted into the circulation as a precursor, but it is also expressed in some tissues where it can be activated locally. This review discusses the specific tissue expression of the components of the chemerin system, and the role of different proteases in regulating the activation and inactivation of chemerin. Methods of identifying and determining the levels of different chemerin forms in both mass and activity assays are reviewed. The levels of chemerin in circulation are correlated with certain disease conditions, such as patients with obesity or diabetes, leading to the possibility of using chemerin as a biomarker." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal

March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in class innovative cancer therapies. Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered

VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate

live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands,

With continued study of their function and mechanism of action, there is a greater understanding of how

molecular docking results showed that Polygalaxanthone III, Girinimbine and Pachymic acid performed greater

allosteric sites Allosteric sites offer a more nuanced approach to modulating GPCR activity, enabling greater Moreover, they have the potential to enhance target selectivity, which can arise from greater sequence

Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic

A greater understanding of this function of GPCRs is likely to significantly augment our ability to further

In the next article, we will explore this emerging field in greater detail.

company’s goal is to model receptor dynamics — including biased signaling — to predict drug behavior with greater

Terry’s Corner: Rethinking Affinity, A Critical Edge for Drug Hunters One of the most persistent misconceptions But Terry Kenakin’s new Emerging Drug Hunter lecture reveals why this assumption can mislead even experienced what misleads—practical, real-world expertise designed to help teams move faster, smarter, and with greater just create a productive lab—it accelerated outcomes and laid the cultural foundation for the next generation

The newer generations of targets and screening tools will pave the way for safer and more efficient drugs Greater specificity : allows for selective tracking of receptor subtypes in complex brain tissues.

Shape the next generation of cellular biochemistry research. fragmented feeds and endless searches, Premium is structured to help you move faster, smarter, and with greater pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation

how mentorship and team science are fueling innovation in the field and providing a path for the next generation alerts, job opportunities, and insider commentary—designed to help you move faster, smarter, and with greater Kenakin) teaming up with the best GPCR community platform to help train and inspire the next generation

professional threat of falling behind your peers by accessing the same insights that are driving the next generation , job opportunities, and insider commentary—all designed to help you move faster, smarter, and with greater

These are not “gentler” mechanisms—they are more system-aware  mechanisms, a crucial distinction in modern

It's all for the greater good!

Moreover, they have the potential to enhance target selectivity, which can arise from greater sequence

General structure of ligands architecture obtained by Celtarys Technology. Seven fluorescent ligands with P1 and P3 pharmacophores were characterized biologically in greater depth

, in contrast with CCR2, indicating that β-arrestin regulates scavenging and signaling of CCR1 to a greater

construction and metric definition where data is classified and compared; and 3) detection, prediction, or generation For this reason, DL models generally require more computational resources (such as powerful GPUs) and De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding limitation holds when searching for novel receptor ligands, as “ligand-based approaches often bias molecule generation Greater application of unsupervised machine learning: most applications of ML in GPCR drug discovery